Scholars Central

Conference abstractPublished 27 Jul 2018

Molecular analysis of Respiratory Syncytial Virus (RSV) F and G proteins during the 2015-2017 winter seasons in the USA and viral susceptibility to anti-RSV monoclonal antibody (mAbs)

Authors: Bin Lu, Hong Jin, Hui Liu, Fiona Fernandes, Weijia Wang, David Tabor, Seme Diallo, Alexey Ruzin, Qing Zhu, Mark Esser, JoAnn Suzich

MedImmune, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

RSV is a leading cause of lower respiratory tract infections in infants. Palivizumab is the only approved agent for RSV prophylaxis limited to high-risk infants. MEDI8897, a potent anti-RSV F mAb with extended serum half-life, is under clinical investigation as a candidate for RSV passive vaccination in all infants entering their first RSV season. To monitor current RSV genotypes in circulation and natural polymorphisms in the F protein-binding regions of MEDI8897 and palivizumab, we determined G and F sequences of 1,228 RSV isolates collected in the OUTSMART surveillance program during 2015-16 (n=392) and 2016-17 (n=836) RSV seasons from 25 regional laboratories in the US and Puerto Rico. RSV A (62% in 2015- 16 and 45% in 2016-17), RSV B (37% in 2015-16 and 54% in 2016-17), and RSVA/RSVB coinfection (1% in both seasons) were detected. All RSV A and RSV B isolate clustered into ON1 and BA genotypes, respectively. A few distinct substitution polymorphisms in the MEDI8897 binding region (AA62-69 and 196-212) of the F protein were identified in RSV A (residues 65, 68 or 206) and RSV B (residues 66, 209, 210 and double 201/209, 206/209) strains. The frequency of these variants was in the 0.2-2.1% range, except for the 206/209 variant detected at a frequency of ~19% in 2016-17. None of these F polymorphisms had an impact on viral susceptibility to MEDI8897 neutralization. One known palivizumab resistant variant at residue 272 of RSV A was observed in the palivizumab binding region (AA267-275). The ongoing OUTSMART study provides viral susceptibility monitoring for anti-RSV mAbs.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Virology & Mycology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalVirology & Mycology
  • SubjectInfectious Diseases
  • SubjectMicrobiology
  • BylineArticles whose byline prints “Bin Lu”
  • BylineArticles whose byline prints “Hong Jin”
  • BylineArticles whose byline prints “Hui Liu”
  • BylineArticles whose byline prints “Fiona Fernandes”
  • BylineArticles whose byline prints “Weijia Wang”
  • BylineArticles whose byline prints “David Tabor”
  • BylineArticles whose byline prints “Seme Diallo”
  • BylineArticles whose byline prints “Alexey Ruzin”